HEALTH● LOW3d ago · Oct 24, 2026, 5:45 AM
Moderna - Merck personalized mRNA melanoma vaccine cuts relapse risk in late - stage trial
wgxa.tv · United States · global
A personalized mRNA melanoma vaccine developed by Moderna and Merck has shown to reduce the risk of relapse in a late-stage trial. This development could significantly impact melanoma treatment.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text.
See it on the live mapUnited States and nearby eventsMore from United StatesLatest stories and threat level
More from United States
BUSINESS4h ago21 years ago, Walmart pledged to protect one acre for every acre it developed: since then, the program has helped protect more than 2.2 million acres in the United StatesClarínPOLITICS20h agoMidterms in the United States: Abdul El-Sayed, Trump's bête noire who could swing the SenateLe Figaro InternationalWORLD1d agoF1: Antonelli two points from title after winning United States Grand PrixANSA [en]WORLD1d agoUnited States Grand Prix : Formula 1 Teams & Drivers report from COTAgrandprix247.com · Australia
More in Health
HEALTH25m agoKatsina Intensifies Ebola Surveillance, Strengthens Diphtheria Response Ahead Of Polio CampaignChannels TVHEALTH52m agoKenya: 20 Ebola contacts released from quarantineUN NewsHEALTH1h agoMarijuana and violence: How much more evidence do we need of the connection?The HillHEALTHBREAKING1h agoDR Congo reports over 10,000 Ebola cases as the outbreak spreads abroad, with no approved vaccine or specific treatment for the Bundibugyo virusDW News [en]